Curcumin-laden dual-targeting fucoidan/chitosan nanocarriers for inhibiting brain inflammation via intranasal delivery.
Int J Biol Macromol
; 181: 835-846, 2021 Jun 30.
Article
en En
| MEDLINE
| ID: mdl-33857519
ABSTRACT
Curcumin can reduce the production of brain inflammatory mediators and symptoms of brain diseases. However, a large amount of free curcumin needs to be administered to achieve an effective level in the brain because of its poor water-solubility. Fucoidan and chitosan were reported to respectively target P-selectin and acidic microenvironment expressed by pathologically inflammatory cells/tissues. Herein, the self-assembly of chitosan and fucoidan which could encapsulate curcumin was developed to form the multi-stimuli-responsive nanocarriers, and their pathological pH- and P-selectin-responsive aspects were characterized. Through intranasal delivery to the brain, these curcumin-containing chitosan/fucoidan nanocarriers with dual pH-/P-selectin-targeting properties to the brain lesions improved drug delivery, distribution, and accumulation in the inflammatory brain lesions as evidenced by an augmented inhibitory effect against brain inflammation. This promising multifunctional nanocarrier with a novel drug-delivery route should allow potential clinical biomedical uses by neurosurgeon in the future.
Palabras clave
Texto completo:
1
Bases de datos:
MEDLINE
Métodos Terapéuticos y Terapias MTCI:
Terapias_biologicas
/
Aromoterapia
/
Plantas_medicinales
Asunto principal:
Polisacáridos
/
Portadores de Fármacos
/
Sistemas de Liberación de Medicamentos
/
Curcumina
/
Quitosano
/
Encefalitis
/
Nanopartículas
Idioma:
En
Revista:
Int J Biol Macromol
Año:
2021
Tipo del documento:
Article
País de afiliación:
Taiwán